GlassScriptPhysician profile
Larry N Elam
NPI 1306844170
$3,874.91
in general payments reported to CMS, 2019-2025
25 companies · $516 in 2025
The $516 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $122 · 2021: $559 · 2022: $870 · 2023: $1,114 · 2024: $412 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,917 · Long Term Medical Supply Or Device Loan: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.08 |
| Long Term Medical Supply Or Device Loan | $123.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,139.36 | 2021-2024 | Qelbree, Qelbree |
| Corium, LLC | $652.55 | 2021-2025 | Azstarys |
| Tris Pharma INC | $398.06 | 2020-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $347.94 | 2019-2024 | Jornay Pm |
| Sobi, INC | $182.06 | 2019-2024 | |
| Glaxosmithkline, LLC. | $158.54 | 2019-2025 | Bexsero, Rotarix |
| Pfizer INC. | $147.57 | 2022-2025 | |
| Sanofi Pasteur INC. | $145.06 | 2019-2025 | |
| Baxter Healthcare | $123.96 | 2025 | Hillrom - Spot Vision Screener |
| Adlon Therapeutics L.P. | $114.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $79.82 | 2021-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Kaleo, INC. | $56.29 | 2019 | |
| Genentech USA, INC. | $52.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.96 | 2020 | |
| Seqirus USA INC | $38.95 | 2022-2023 | Flucelvax Quadrivalent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $27.80 | 2025 | Neffy |
| Phadia US INC. | $23.45 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.66 | 2023 | |
| Collegium Pharmaceutical, INC. | $22.17 | 2025 | Jornay Pm |
| Ironwood Pharmaceuticals, INC | $22.05 | 2024 | |
| Azurity Pharmaceuticals, INC. | $15.40 | 2025 | Zonisade |
| Mylan Pharmaceuticals INC. | $15.31 | 2019 | |
| Shire North American Group INC | $14.98 | 2019 | |
| Boston Scientific Corporation | $14.07 | 2019 | |
| Neos Therapeutics, LP | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Elam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.